Alnylam Pharmaceuticals presented new clinical and real‑world data on its RNAi therapy vutrisiran at the American College of Cardiology’s Annual Scientific Session (ACC.26), which ran March 28‑30, 2026. The data focused on patients with transthyretin‑mediated cardiomyopathy (ATTR‑CM) and demonstrated sustained efficacy and quality‑of‑life improvements comparable to patients 11 years younger.
The study showed significant gains in physical limitations and overall quality of life, reinforcing the therapeutic advantage of vutrisiran’s subcutaneous injection over oral competitors such as tafamidis and acoramidis. These findings strengthen Alnylam’s position as a leading RNAi platform in a high‑growth, high‑margin market and support the company’s strategy to expand its ATTR‑CM portfolio.
Alnylam’s focus on ATTR‑CM has been a core driver of revenue and profitability. The company achieved profitability for the first time in 2025, largely due to the rapid growth of its transthyretin franchise, particularly Amvuttra. The new data provide fresh evidence to clinicians and payers, potentially accelerating market adoption and underpinning the company’s 2026 revenue guidance, which projects significant growth for the TTR franchise.
In February 2026, CEO Yvonne Greenstreet emphasized that Alnylam expects to sustain profitability, driven by the expanding transthyretin franchise. She also outlined the “Alnylam 2030” strategy, which focuses on scaling operations through durable ATTR leadership, long‑term sustainable innovation, and exceptional financial results.
The ACC.26 presentation is a significant operational milestone that not only reinforces Amvuttra’s clinical value but also bolsters Alnylam’s competitive advantage in the ATTR‑CM market. The data support the company’s broader strategy to leverage its RNAi platform across additional therapeutic areas, positioning Alnylam for continued growth and market leadership.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.